Human Urinary GM2-activator Protein as a Potential Biomarker for Lung Cancer

Potprommanee, Laddawan; Ma, Haou-Tzong; Chen, Chein‐Hung; Aobchey, Paitoon; Boonyapranai, Kongsak; Chewaskulyong, Busyamas; Sangthong, Padchanee; Shank, Lalida; Chen, Shui‐Tein

doi:10.4172/jpb.1000289

Cited by 4 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the upregulated spots, GM2AP was present at 2.5 to 4.0 folds higher than the level found in healthy volunteers. Those results were consistent with the recent findings reported in the study by Potprommanee et al 6 They used 2-DE and 2-DE Western blotting in the 2-DE region to confirm the expression of urinary GM2AP level of individual patients with lung cancer. The urinary GM2AP level was found to increase in patient with lung cancer compared with that the healthy volunteers, suggesting that the urinary GM2AP level is potentially useful as a biomarker for lung cancer.…”

Section: Discussionsupporting

confidence: 92%

GM2-Activator Protein: A New Biomarker for Lung Cancer

Potprommanee

Shank

et al. 2015

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

GM2-Activator Protein: A New Biomarker for Lung Cancer

Potprommanee

Shank

et al. 2015

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…S1D) and used to extract protein from urine, as described by Potprommanee et al. with slight modifications . The detailed optimization and 2DE protocol are shown in Supporting Information Section 2.…”

Section: Methodsmentioning

confidence: 99%

Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics

et al. 2016

View full text Add to dashboard Cite

Globally, breast cancer is the second most common cancer among women. Although biomarker discoveries through various proteomic approaches of tissue and serum samples have been studied in breast cancer, urinary proteome alterations in breast cancer are least studied. Urine being a noninvasive biofluid and a significant source of proteins, it has the potential in early diagnosis of breast cancer. This study used complementary quantitative gel-based and gel-free proteomic approaches to find a panel of urinary protein markers that could discriminate HER2 enriched (HE) subtype breast cancer from the healthy controls. A total of 183 differentially expressed proteins were identified using three complementary approaches, namely 2D-DIGE, iTRAQ, and sequential window acquisition of all theoretical mass spectra. The differentially expressed proteins were subjected to various bioinformatics analyses for deciphering the biological context of these proteins using protein analysis through evolutionary relationships, database for annotation, visualization and integrated discovery, and STRING. Multivariate statistical analysis was undertaken to identify the set of most significant proteins, which could discriminate HE breast cancer from healthy controls. Immunoblotting and MRM-based validation in a separate cohort testified a panel of 21 proteins such as zinc-alpha2-glycoprotein, A2GL, retinol-binding protein 4, annexin A1, SAP3, SRC8, gelsolin, kininogen 1, CO9, clusterin, ceruloplasmin, and α1-antitrypsin could be a panel of candidate markers that could discriminate HE breast cancer from healthy controls.

show abstract

High expression of SOX30 is associated with favorable survival in human lung adenocarcinoma

Han

Liu

Xiao

et al. 2015

Sci Rep

View full text Add to dashboard Cite

In our previous study, we had identified SOX30 as a novel tumor suppressor that acts through direct regulation of p53 transcription in human lung cancer. Here, we sought to determine the clinical relevance of SOX30 expression in a series of surgically-resected non-small cell lung cancer (NSCLC) patients. Analysis of SOX30 expression and clinico-pathologic features reveal a significant correlation of SOX30 expression with histological type (n = 220, P = 0.008) and clinical stage (n = 220, P = 0.024). Kaplan-Meier analysis indicates an association of high SOX30 expression with better prognosis in NSCLC patients (n = 220, P = 0.007). Via multivariate Cox-regression analysis, SOX30 expression is revealed to be an independent prognostic factor for overall survival (OS) of NSCLC patients (n = 220, P = 0.014, hazard ratio (HR) = 0.816). In particular, SOX30 is a favorable and independent prognostic factor in one main subtype of NSCLC, lung adenocarcinoma (ADC) patients (n = 150, P = 0.000, HR = 0.405), but not in another main subtype of NSCLC, squamous cell carcinoma patients. Furthermore, high expression of SOX30 represents a favorable and independent factor for the prognosis of ADC patients at clinical stage II (P = 0.013), with positive lymph node (P = 0.003), at histological grade 2 (P = 0.000) or grade 3 (P = 0.025). In summary, SOX30 expression represents an important prognostic factor for survival time in ADC patients.

show abstract

Human Urinary GM2-activator Protein as a Potential Biomarker for Lung Cancer

Cited by 4 publications

References 23 publications

GM2-Activator Protein: A New Biomarker for Lung Cancer

GM2-Activator Protein: A New Biomarker for Lung Cancer

Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics

High expression of SOX30 is associated with favorable survival in human lung adenocarcinoma

Contact Info

Product

Resources

About